Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics. Its lead product candidate is Deramiocel, an allogeneic cardiosphere-derived cell therapy currently in Phase 3 clinical trials for the treatment of Duchenne muscular dystrophy (DMD). The company also has an exosome protein-based vaccine in preclinical trials targeting SARS-CoV-2, as well as the StealthX Exosome Platform, which includes engineered exosomes for vaccine and therapeutic development. Additionally, Capricor is developing StealthX, an engineered exosome-based vaccine candidate under Phase 1 clinical study for applications such as targeted RNA, protein, and small molecule therapeutics. The company's pipeline addresses diseases with unmet medical needs, primarily in the United States.

Capricor Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CAPR. The company's shares are traded in U.S. dollars (USD), reflecting its primary operations and headquarters in the United States. As a Nasdaq-listed company, Capricor is subject to the exchange's listing requirements and regulatory oversight, providing investors with a transparent trading environment.

Capricor Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies using cell and exosome-based technologies. The company's work is centered on addressing serious diseases like Duchenne muscular dystrophy (DMD) and other conditions with limited treatment options, positioning it within the broader biotech landscape that emphasizes cutting-edge scientific research and clinical development.

Capricor Therapeutics is headquartered in San Diego, California, United States. Founded in 2005, the company primarily serves the U.S. market, focusing on developing therapies for diseases with unmet medical needs. Its clinical trials and research activities are conducted in the United States, and it holds license agreements with U.S. institutions such as Johns Hopkins University and Cedars-Sinai Medical Center, as well as the University of Rome. The company's geographic focus is on the U.S. healthcare system, though its technologies have potential global applications.

Capricor Therapeutics' lead product candidate is Deramiocel, an allogeneic cardiosphere-derived cell therapy in Phase 3 trials for Duchenne muscular dystrophy (DMD). The company also has an exosome protein-based vaccine in preclinical trials for SARS-CoV-2 and the StealthX Exosome Platform, which includes engineered exosomes for vaccine and therapeutic development. StealthX, an engineered exosome-based vaccine candidate, is under Phase 1 clinical study for targeted RNA, protein, and small molecule therapeutics. Capricor has license agreements with Johns Hopkins University, the University of Rome, and Cedars-Sinai Medical Center to develop and commercialize licensed products and services. Additionally, it holds a Cell Line License Agreement with Life Technologies for exosome platform development.